Search terms

Home
Philips
IntraSight Interventional applications platform

IntraSight

Interventional applications platform

Find similar products

The IntraSight applications platform is where imaging, physiology, co-registration* and software all come together to clearly identify coronary and peripheral artery disease, and allow for more optimized treatment plans. IntraSight is built on a new foundational platform designed to meet the evolving needs of your lab today and tomorrow.

Contact us

Specifications

Power requirements
Power requirements
System input
  • 100, 120v, 220, 240VAC, 50/60Hz, 1000Va
Monitor
  • 100V – 240V 50/60Hz, 39W
Workstation
  • 100 – 240V, 50/60Hz, 825VA
Dimensions
Dimensions
Workstation
  • H=17", W=10", D=16.5"
Monitor
  • H=15"-19", W=15.8", D=9.7"
Control pad (optional)
  • H=2.75"-19", W=10.5", D=8.3"
Connection box
  • H=9.95", W=2.95",D=7.75"
Touch screen module with articulating tableside mount
  • H=7”, W=11.9”, D=9” (articulating arm extends to a depth of 16.5” and/or 20” above the bedrail)
Control room controller
  • H=5", W=15", D=10"
Processing and data storage
Processing and data storage
Processor
  • 1 CPU with 2.3GHz (maximum turbo frequency of 3.2GHz) 12 core total, 2400 MHz BUS
Hard drive capacity
  • 1TB SSD SATA
DICOM services supported
  • DICOM worklist management, DICOM store
Memory
  • 32GB SD RAM
Digital archiving capacity
  • Local, DVD, DICOM Network (including Worklist management, DICOM Store)
Ordering Information
Ordering Information
IntraSight 7 configuration
  • IntraSight07
IntraSight 5 configuration
  • IntraSight05
  • 1. Davies JE, et al., Use of the Instantaneous Wave-free Ration or Fractional Flow Reserve in PCI. N Engl J Med. 2017 May 11;376(19):1824-1834.
  • 2. Patel M. “Cost-effectiveness of instantaneous wave-Free Ratio (iFR) compared with Fractional Flow Reserve (FFR) to guide coronary revascularization decision making.” Late-breaking Clinical Trial presentation at ACC on March 10, 2018.
  • 3. Witzen B et al. Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents: The ADAPT-DES Study. Circulation 2014 Jan: 129,4;463-470.
  • *Co-registration tools available within IntraSight 7 configuration via SyncVision

By clicking on the link, you will be leaving the official Royal Philips Healthcare ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.

I understand